209 related articles for article (PubMed ID: 31171223)
21. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry.
Chen S; Kong H; Lu X; Li Y; Yin P; Zeng Z; Xu G
Anal Chem; 2013 Sep; 85(17):8326-33. PubMed ID: 23889541
[TBL] [Abstract][Full Text] [Related]
22. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
[TBL] [Abstract][Full Text] [Related]
23. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.
Alberice JV; Amaral AF; Armitage EG; Lorente JA; Algaba F; Carrilho E; Márquez M; García A; Malats N; Barbas C
J Chromatogr A; 2013 Nov; 1318():163-70. PubMed ID: 24139504
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
Jin X; Yun SJ; Jeong P; Kim IY; Kim WJ; Park S
Oncotarget; 2014 Mar; 5(6):1635-45. PubMed ID: 24721970
[TBL] [Abstract][Full Text] [Related]
25. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
26. Molecular signature of renal cell carcinoma by means of a multiplatform metabolomics analysis.
Kordalewska M; Wawrzyniak R; Jacyna J; Godzień J; López Gonzálves Á; Raczak-Gutknecht J; Markuszewski M; Gutknecht P; Matuszewski M; Siebert J; Barbas C; Markuszewski MJ
Biochem Biophys Rep; 2022 Sep; 31():101318. PubMed ID: 35967759
[TBL] [Abstract][Full Text] [Related]
27. Proteomics Profiling of Bladder Cancer Tissues from Early to Advanced Stages Reveals NNMT and GALK1 as Biomarkers for Early Detection and Prognosis of BCa.
Davalieva K; Kiprijanovska S; Ivanovski O; Trifunovski A; Saidi S; Dimovski A; Popov Z
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834386
[TBL] [Abstract][Full Text] [Related]
28. Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review.
Pereira F; Domingues MR; Vitorino R; Guerra IMS; Santos LL; Ferreira JA; Ferreira R
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542319
[TBL] [Abstract][Full Text] [Related]
29. Discovering biomarkers in bladder cancer by metabolomics.
Zhang WT; Zhang ZW; Guo YD; Wang LS; Mao SY; Zhang JF; Liu MN; Yao XD
Biomark Med; 2018 Dec; 12(12):1347-1359. PubMed ID: 30507300
[TBL] [Abstract][Full Text] [Related]
30. Raman chemometric urinalysis (Rametrix) as a screen for bladder cancer.
Huttanus HM; Vu T; Guruli G; Tracey A; Carswell W; Said N; Du P; Parkinson BG; Orlando G; Robertson JL; Senger RS
PLoS One; 2020; 15(8):e0237070. PubMed ID: 32822394
[TBL] [Abstract][Full Text] [Related]
31. Urinary metabolomics of pregnant women at term: a combined GC/MS and NMR approach.
Caboni P; Meloni A; Lussu M; Carta E; Barberini L; Noto A; Deiana SF; Mereu R; Ragusa A; Paoletti AM; Melis GB; Fanos V; Atzori L
J Matern Fetal Neonatal Med; 2014 Oct; 27 Suppl 2():4-12. PubMed ID: 25284171
[TBL] [Abstract][Full Text] [Related]
32. Targeting metabolomics analysis of the sunscreen agent 2-ethylhexyl 4-(N,N-dimethylamino)benzoate in human urine by automated on-line solid-phase extraction-liquid chromatography-tandem mass spectrometry with liquid chromatography-time-of-flight/mass spectrometry confirmation.
León-González Z; Ferreiro-Vera C; Priego-Capote F; de Castro MD
J Chromatogr A; 2011 May; 1218(20):3013-21. PubMed ID: 21481400
[TBL] [Abstract][Full Text] [Related]
33. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Cana F; Herranz R; Pérez-Ardavín J; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
World J Urol; 2022 Oct; 40(10):2387-2398. PubMed ID: 36057894
[TBL] [Abstract][Full Text] [Related]
34. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
Peng J; Chen YT; Chen CL; Li L
Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
[TBL] [Abstract][Full Text] [Related]
35. Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics.
Shao CH; Chen CL; Lin JY; Chen CJ; Fu SH; Chen YT; Chang YS; Yu JS; Tsui KH; Juo CG; Wu KP
Oncotarget; 2017 Jun; 8(24):38802-38810. PubMed ID: 28415579
[TBL] [Abstract][Full Text] [Related]
36. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
37. Multi-platform metabolomics assays for human lung lavage fluids in an air pollution exposure study.
Surowiec I; Karimpour M; Gouveia-Figueira S; Wu J; Unosson J; Bosson JA; Blomberg A; Pourazar J; Sandström T; Behndig AF; Trygg J; Nording ML
Anal Bioanal Chem; 2016 Jul; 408(17):4751-64. PubMed ID: 27113461
[TBL] [Abstract][Full Text] [Related]
38. Untargeted metabolomics of bladder tissue using liquid chromatography and quadrupole time-of-flight mass spectrometry for cancer biomarker detection.
Nizioł J; Ossoliński K; Płaza-Altamer A; Kołodziej A; Ossolińska A; Ossoliński T; Krupa Z; Ruman T
J Pharm Biomed Anal; 2024 Mar; 240():115966. PubMed ID: 38217999
[TBL] [Abstract][Full Text] [Related]
39. Quantitative determination of potential urine biomarkers of respiratory illnesses using new targeted metabolomic approach.
Khamis MM; Adamko DJ; Purves RW; El-Aneed A
Anal Chim Acta; 2019 Jan; 1047():81-92. PubMed ID: 30567667
[TBL] [Abstract][Full Text] [Related]
40. Metabolomics study on the biochemical profiles of odor elements in urine of human with bladder cancer.
Jobu K; Sun C; Yoshioka S; Yokota J; Onogawa M; Kawada C; Inoue K; Shuin T; Sendo T; Miyamura M
Biol Pharm Bull; 2012; 35(4):639-42. PubMed ID: 22466574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
